WHO WE ARE
Every patient matters
Our pipeline contains novel therapies designed to address debilitating central nervous system (CNS) disorders in order to improve quality of life and patient outcomes.
We partner with patients, families and caregivers, and healthcare professionals to provide a comprehensive approach beyond treating symptoms to ensure that patients’ experiences, perspectives, needs, and priorities are meaningfully incorporated into our work.
A History of Success
Our leadership team has extensive experience with global biotech and pharmaceutical companies and a proven track record of developing and commercializing treatments for central nervous system (CNS) disorders.

The Noema Team

Ilise Lombardo, MD
Chief Executive Officer

George Garibaldi, MD
President Research & Development

Mike Gutch, Ph.D.
Chief Financial Officer

Sally Nixon
Head of Operations

Renata Lazarova, MD
VP Clinical Development, Pediatric Programs

Amine Tahiri PharmD, MBA
VP Clinical Development, Adult Programs

Simon Roitt, Ph.D.
VP, Head of Clinical Operations

Smiljana Milosavljevic Ristic, MD, Ph.D.
VP Clinical Development, Behavioral Medicine Programs

Sally Barennes, Ph.D., MBA
VP Pharma Research & Development Strategy

Michel David
VP CMC & Clinical Supply

Jessica Kardish
Global Head of Clinical and Regulatory Operations

Rachel Gurrell
Head of Research and Early Development